A CRISPR-Cas9 based strategy, which consists in positively and specifically modulating the expression of any gene of interest with a catalytically dead Cas9, has also been successfully used to promote Scn1a expression in mouse models of Dravet syndrome (Colasante et al., 2020; Yamagata et al., 2020). The gene discussed is SCN1A; the disease is encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.